- RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This study is looking at a new treatment called petosemtamab for advanced head and neck cancer. It compares this new drug with standard treatments chosen by doctors, for patients whose cancer has come back or spread after previous therapies.
For: Head and Neck Squamous Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This study compares a new treatment combining petosemtamab and pembrolizumab with pembrolizumab alone for advanced head and neck cancer. It aims to see if the combination works better and is safe for patients whose cancer has come back or spread.
For: Head and Neck Squamous Cell CarcinomaUnited States · Argentina · Australia